Cardinal Health (CAH) put its Chinese operations up for sale, drawing interest from state-backed pharmaceutical firms who could pay up to $1.5 billion for the business, Reuters reported.

Shanghai Pharmaceutical Holding Co Ltd, China Resources Pharmaceutical Group Ltd and Sinopharm Group Co Ltd have each expressed interest in buying Cardinal's China operations. Cardinal is one of China's largest drug distributors.

The Ohio-based company is said to seek an exit from the Chinese market ahead of the country's upcoming drug distribution reform that Cardinal thinks might weigh on its growth. Cardinal has also focused on diversification recently, purchasing Medtronic's (MDT) $6.1 billion medical supplies unit in April.

The first round of bidding for the operations is due around Friday. Cardinal's China business generated over $3.5 billion in revenue last year, up from $3 billion in 2015.

Cardinal stock closed flat Wednesday.

More of What's Trending on TheStreet:

More from Life Insurance

How to Protect Yourself and Your Family From Long-Term Care Insurance Scams

How to Protect Yourself and Your Family From Long-Term Care Insurance Scams

Why Property & Casualty Insurance Should Not Be Optional

Why Property & Casualty Insurance Should Not Be Optional

Seven Common Financial Regrets You Want to Avoid

Seven Common Financial Regrets You Want to Avoid

Could Walmart Be the One to Disrupt Healthcare?

Could Walmart Be the One to Disrupt Healthcare?

Why Going to Urgent Care Is Better Than the ER

Why Going to Urgent Care Is Better Than the ER